We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+3.91%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$245M
AUM Growth
+$31M
Cap. Flow
+$33M
Cap. Flow %
13.48%
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49

Top Buys

Rank Stock Value
1
JNK icon
State Street SPDR Bloomberg High Yield Bond ETF
JNK
+$1.9M
2
COIN icon
Coinbase
COIN
+$1.35M
3
DOCU
DocuSign
DOCU
+$1.32M
4
SPOT icon
Spotify
SPOT
+$1.28M
5
UAL icon
United Airlines
UAL
+$1.28M

Top Sells

Rank Stock Value
1
APP icon
Applovin
APP
+$1.14M
2
EXPE icon
Expedia Group
EXPE
+$1.04M
3
KKR icon
KKR & Co
KKR
+$976K
4
CME icon
CME Group
CME
+$974K
5
CPAY icon
Corpay
CPAY
+$948K

Sector Composition

Rank Sector Weight
1 Financials 29.48%
2 Technology 14.86%
3 Healthcare 14.81%
4 Industrials 11.61%
5 Consumer Discretionary 6.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBX
426
MBX Biosciences
MBX
$2.86B
$63.9K 0.03%
+3,468
New +$73.9K
KURA icon
427
Kura Oncology
KURA
$826M
$63.9K 0.03%
7,336
+3,061
+72% +$44K
IMVT icon
428
Immunovant
IMVT
$7.99B
$63.8K 0.03%
2,577
-885
-26% -$25.1K
STOK icon
429
Stoke Therapeutics
STOK
$1.83B
$63.6K 0.03%
5,770
+514
+10% +$6.32K
WVE icon
430
Wave Life Sciences
WVE
$1.13B
$63.5K 0.03%
5,133
-9,089
-64% -$121K
GLUE icon
431
Monte Rosa Therapeutics
GLUE
$1.86B
$63.3K 0.03%
+9,126
New +$68.5K
RNAC icon
432
Cartesian Therapeutics
RNAC
$225M
$63.3K 0.03%
+3,533
New +$71.5K
SLRN
433
DELISTED
ACELYRIN
SLRN
$63.1K 0.03%
20,083
-1,055
-5% -$5.11K
RGNX icon
434
Regenxbio
RGNX
$615M
$63K 0.03%
8,153
+1,110
+16% +$10.4K
BEAM icon
435
Beam Therapeutics
BEAM
$2.7B
$62.8K 0.03%
2,534
-1,119
-31% -$28.6K
ANAB icon
436
AnaptysBio
ANAB
$1.54B
$62.7K 0.03%
4,733
+936
+25% +$22.7K
AUTL
437
Autolus Therapeutics
AUTL
$386M
$62.1K 0.03%
26,429
+6,081
+30% +$20.6K
JANX icon
438
Janux Therapeutics
JANX
$915M
$61.9K 0.03%
1,156
-1,022
-47% -$54.1K
DNLI icon
439
Denali Therapeutics
DNLI
$3.82B
$61.7K 0.03%
3,029
-1,135
-27% -$29.1K
RCUS icon
440
Arcus Biosciences
RCUS
$3.4B
$61.7K 0.03%
4,143
-1,281
-24% -$20.9K
OLMA icon
441
Olema Pharmaceuticals
OLMA
$1.01B
$61.7K 0.03%
10,579
+3,185
+43% +$31.8K
RLAY icon
442
Relay Therapeutics
RLAY
$3.99B
$61.3K 0.03%
14,873
+3,092
+26% +$16.8K
RNAM
443
DELISTED
Avidity Biosciences
RNAM
$61.2K 0.03%
2,106
-199
-9% -$8.32K
NTLA icon
444
Intellia Therapeutics
NTLA
$1.52B
$61.1K 0.03%
5,242
+1,692
+48% +$26.4K
KROS icon
445
Keros Therapeutics
KROS
$199M
$61.1K 0.02%
3,857
+1,998
+107% +$104K
CMPS
446
Compass Pathways
CMPS
$1.46B
$60.9K 0.02%
16,121
+2,840
+21% +$14.4K
GPCR icon
447
Structure Therapeutics
GPCR
$3.4B
$60.8K 0.02%
2,242
+455
+25% +$16.1K
ARWR icon
448
Arrowhead Research
ARWR
$12.1B
$60.4K 0.02%
3,211
-267
-8% -$5.5K
TERN
449
DELISTED
Terns Pharmaceuticals
TERN
$59.8K 0.02%
10,788
-762
-7% -$5.16K
VKTX icon
450
Viking Therapeutics
VKTX
$3.93B
$59.8K 0.02%
1,485
-286
-16% -$16.3K
16 17
18
19 20

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2024 Portfolio in Review

As of Q4 2024, Virtus ETF Advisers held 511 positions worth $245M, up 15% from $214M the previous quarter. Its ten largest holdings account for 7.3% of the portfolio.

Virtus ETF Advisers deployed $33M of net new capital in Q4 2024, opening 57 new positions and adding to 251 existing holdings. Its largest new stake was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.

By sector, the portfolio is most concentrated in Financials at 29% of assets, up from 28% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Applovin, an estimated $1.14M trimmed.

  • Virtus ETF Advisers's largest Q4 2024 buy was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.
  • Virtus ETF Advisers added most to Eagle Point Credit Company in Q4 2024, an estimated $515K increase.
  • Virtus ETF Advisers's biggest Q4 2024 reduction was Applovin, cutting an estimated $1.14M.
  • Virtus ETF Advisers fully exited Expedia Group in Q4 2024, selling an estimated $1.04M.
  • Virtus ETF Advisers's ten largest holdings make up 7.3% of its $245M portfolio in Q4 2024.
  • Virtus ETF Advisers opened 57 new positions and closed 49 in Q4 2024.
  • Virtus ETF Advisers's portfolio value rose 15% quarter-over-quarter to $245M.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.